Comparison of the effects of thioridazine and mesoridazine on the QT interval in healthy adults after single oral doses

Clinical Pharmacology and Therapeutics

Volumn 82, Issue 5, 2007, Pages 548-554

  Salih, I S M ^a   Thanacoody, R H K ^a   McKay, G A ^a   Thomas, S H L ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; MESORIDAZINE BESYLATE; PLACEBO; THIORIDAZINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; FEMALE; HEART RATE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE;

ADMINISTRATION, ORAL; ADULT; ANTIPSYCHOTIC AGENTS; AREA UNDER CURVE; CROSS-OVER STUDIES; DOPAMINE ANTAGONISTS; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; HEART CONDUCTION SYSTEM; HUMANS; LONG QT SYNDROME; MALE; MESORIDAZINE; MIDDLE AGED; REFERENCE VALUES; THIORIDAZINE;

EID: 35248875421     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100194     Document Type: Article

References (32)

1. Thomas, S.H.L. QT interval prolongation and ventricular arrhythmias. Adverse Drug React. Toxicol. Rev. 13, 77-102 (1994).
2. Kelly, H.Q., Fay, J.E. & Laverty, F.G. Thioridazine hydrochloride (Mellaril): its effect on the electrocardiogram and a report of two fatalities with electrocardiographic abnormalities. Can. Med. Assoc. J. 89, 546-554 (1963).
3. Mehtonen, O.P., Aranko, K., Malkonen, L. & Vapaatalo, H. A survey of sudden death associated with the use of antipsychotic or antidepressant drugs: 49 cases in Finland. Acta Psychiat. Scan. 84, 58-64 (1991).
4. Ray, W.A., Meredith, S., Thapa, P.B., Meador, K.G., Hall, K. & Murray, K.T. Antipsychotics and the risk of sudden cardiac death. Arch. Gen. Psychiatry 59, 1161-1167 (2001).
5. Reilly, J.G., Ayis, S.A., Ferrier, I.N., Jones, S.J. & Thomas, S.H. Thioridazine and sudden unexplained death in psychiatric inpatients. Br. J. Psychiatry 180, 515-522 (2002).
6. Drolet, B. et al. Thioridazine lengthens repolarisation of cardiac ventricular myocytes by blocking the delayed rectifier potassium current. J. Pharmacol. Exp. Ther. 288, 1261-1269 (1999).
7. Tie, H., Walker, B.D., Valenzuela, S.M., Breit, S.N. & Campbell, T.J. The heart of psychotropic drug therapy. Lancet 355, 1825 (2001).
8. Hartigan-Go, K., Bateman, D.N., Nyberg, G., Martensson, E. & Thomas, S.H.L. Concentration-related pharmacodynamic effects of thioridazine and its metabolites in humans. Clin. Pharmacol. Ther. 60, 543-553 (1996).
9. Gershon, S., Sakalis, G. & Bowers, P.A. Mesoridazine - a pharmacodynamic and pharmacokinetic profile. J. Clin. Psychiatry 42, 463-469 (1981).
10. Su, Z., Martin, R., Cox, B.F. & Gintant, G. Mesoridazine: an open-channel blocker of human ether-a-go-go-related gene K+ channel. J. Mol. Cell Cardiol. 36, 151-160 (2004).
11. Al-Khatib, S.M., LaPointe, N.M.A., Cramer, J.M. & Califf, R.M. What clinicians should know about the QT interval. JAMA 289, 2120-2127 (2003).
12. Dillenkoffer, R.L., Gallant, D.M. & Phillips, J.H. Electrocardiographic evaluation of mesoridazine. Curr. Ther. Res. 14, 71-72 (1972).
13. Niemann, J.T., Stapczynski, J.S., Rothstein, R.J. & Laks, M.M. Cardiac conduction and rhythm disturbances following suicidal ingestion of mesoridazine. Ann. Emerg. Med. 10, 585-588 (1981).
14. Marrs-Simon, P.A., Zell-Kanter, M., Kendzierski, D.L. & Leikin, J.B. Cardiotoxic manifestations of mesoridazine overdose. Ann. Emerg. Med. 17, 1074-1078 (1988).
15. Vertrees, J.E. & Siebel, G. Rapid death resulting from mesoridazine overdose. Vet. Hum. Toxicol. 29, 65-67 (1987).
16. Von Bahr, C., Movin, G. & Nordin, C. Plasma levels of thioridazine and metabolites are influenced by the debrisoquine hydroxylation phenotype. Clin. Pharmacol. Ther. 49, 234-240 (1991).
17. Eap, C.B. et al. Plasma levels of the enantiomers of thioridazine, thioridazine 2-sulfoxide, thioridazine 2-sulfone, and thioridazine 5-sulfoxide in poor and extensive metabolizers of dextromethorphan and mephenytoin. Clin. Pharmacol. Ther. 59, 322-331 (1996).
18. Berecz, R., de la Rubia, A., Dorado, P., Fernandez-Salguero, P., Dahl, M.L. & Llerena, A. Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype. Eur. J. Clin. Pharmacol. 59, 45-50 (2003).
19. Llerena, A., Berecz, R., de la Rubia, A., Noberto, M.J. & Benitez, J. Use of the thioridazine/mesoridazine ratio as a marker of CYP2D6 enzyme activity. Ther. Drug Monit. 22, 397-401 (2000).
20. Carillo, J.A. et al. Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients. J. Clin. Psychopharm. 19, 494-499 (1999).
21. Wojcikowski, J., Maurel, P. & Daniel, W.A. Characterization of human cytochrome p450 enzymes involved in the metabolism of the piperidine-type phenothiazine neuroleptic thioridazine. Drug Metab. Dispos. 34, 471-476 (2006).
22. Von Bahr, C. et al. Inhibition of desmethyimipramine 2′-hydroxylation by drugs in human liver microsomes. Biochem. Pharmacol. 24, 2501-2505 (1985).
23. Llerena, A., Berecz, R., de la Rubia, A., Fernandez-Salguero, P. & Dorado, P. Effect of thioridazine dosage on the debrisoquine hydroxylation phenotype in psychiatric patients with different CYP2D6 genotypes. Ther. Drug Monit. 14, 616-620 (2001).
24. Llerena, A., Berecz, R., de la Rubia, A. & Dorado, P. QTc interval lengthening is related to CYP2D6 hydroxylation capacity and plasma concentration of thioridazine in patients. J. Psychopharmacol. 16, 359-362 (2002).
25. Hale, P.W. Jr & Poklis, A. Thioridazine-5-sulphoxide cardiotoxicity in the isolated, perfused rat heart. Toxicol. Lett. 21, 1-8 (1984).
26. Heath, A. Thioridazine toxicity - an experimental cardiovascular study of thioridazine and its major metabolites in overdose. Vet. Hum. Toxicol. 27, 100 (1985).
27. Thanacoody, R.H.K., Daly, A.K., Reilly, J.G., Ferrier, I.N. & Thomas, S.H.L. Factors affecting drug concentrations and QT interval during thioridazine therapy. Clin. Pharmacol. Ther. (in press).
28. Forrest, I.S., Green, D.E., Blum, A., Serra, M.T. & Loeffler, K.O. Studies on thioridazine and mesoridazine metabolism. I. Protein binding. Commun. Psychopharmacol. 3, 319-322 (1979).
29. Freedberg, K.A., Irris, R.B., Creese, I. & Snyder, S.H. Antischizophrenic drugs: differential plasma protein binding and therapeutic activity. Life Sci. 24, 2467-2474 (1979).
30. 2 receptors in rat brain. Neuropharmacology 27, 1117-1124 (1988).
31. Choi, S., Haggart, D., Toll, L. & Cuny, G.D. Synthesis, receptor binding and functional studies of mesoridazine stereoisomers. Bioorg. Med. Chem. Lett. 14, 4379-4382 (2004).
32. Cohen, B.M., Lipinski, J.F. & Waternaux, C. A fixed dose study of the plasma concentration and clinical effects of thioridazine and its major metabolites. Psychopharmacology 97, 481-488 (1989).